Phase I Trial of Measles Vectored Chikungungya Vaccine
A Phase 1, Double Blinded, Placebo Controlled, Dose Comparison Trial to Evaluate the Safety, Immunogenicity and Schedule of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
A PHASE1 clinical study on Chikungunya Virus Infection, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 12 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Mar 2019 — Dec 2020 [monthly]
Completed PHASE1
▶ Show 7 earlier versions
-
Feb 2019 — Mar 2019 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
-
Dec 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Nov 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .